Pharvaris/$PHVS

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Pharvaris

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Ticker

$PHVS
Sector
Health
Primary listing
NASDAQ

Employees

114

Headquarters

Zug, Switzerland
Website
pharvaris.com

Pharvaris Metrics

BasicAdvanced
$1.6B
-
-$3.58
-2.81
-

What the Analysts think about Pharvaris

Analyst ratings (Buy, Hold, Sell) for Pharvaris stock.

Bulls say / Bears say

Strong financial position with €200 million in cash as of June 30, 2025 and a $201.2 million upsized public offering extends cash runway into the first half of 2027. (Nasdaq)
Pivotal Phase 3 programs de-risked by RAPIDe-3 reaching target enrollment in March 2025 and CHAPTER-3 enrollment progressing as planned, strengthening confidence in the late-stage pipeline. (Nasdaq)
Orphan drug designation granted by the European Commission in March 2025 (following FDA designation in March 2022) provides up to 10 years of market exclusivity in the EU, supporting pricing power and competitive moat. (EMA)
High cash burn with R&D expenses of €29.6 million and a net loss of €45.5 million in Q2 2025, up from €29.7 million a year earlier, raising concerns about financial sustainability without product revenue. (Nasdaq)
Delayed data readouts extend timelines to potential approval and commercialization, with RAPIDe-3 topline results now expected in Q4 2025 and CHAPTER-3 results in H2 2026, prolonging revenue uncertainty. (Nasdaq)
Intense competition from KalVista’s oral HAE therapy Ekterly (sebetralstat), which received FDA approval in July 2025, risks capturing on-demand market share ahead of deucrictibant. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.

Pharvaris Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Pharvaris Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PHVS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs